Galsky MD - Search Results

1

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Ross RW, et al. Among authors: galsky md. Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26. Cancer. 2012. PMID: 22282219 Free PMC article. Clinical Trial.

2

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Galsky MD, et al. J Clin Oncol. 2005 Mar 1;23(7):1439-46. doi: 10.1200/JCO.2005.09.042. J Clin Oncol. 2005. PMID: 15735119 Clinical Trial.

3

Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.

Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Ross RW, et al. Clin Cancer Res. 2005 Jul 15;11(14):5195-8. doi: 10.1158/1078-0432.CCR-05-0431. Clin Cancer Res. 2005. PMID: 16033836

4

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Among authors: galsky md. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

5

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Dash A, et al. Among authors: galsky md. Cancer. 2006 Aug 1;107(3):506-13. doi: 10.1002/cncr.22031. Cancer. 2006. PMID: 16773629 Free article.

6

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Cancer. 2007 Feb 1;109(3):549-55. doi: 10.1002/cncr.22454. Cancer. 2007. PMID: 17200962 Free article. Clinical Trial.

7

Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.

Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Sonpavde G, et al. Among authors: galsky md. Cancer. 2007 Dec 15;110(12):2628-39. doi: 10.1002/cncr.23085. Cancer. 2007. PMID: 17941029 Free article. Review.

8

Novel agents for muscle-invasive and advanced urothelial cancer.

Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. Among authors: galsky md. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.

9

Docetaxel-based combination therapy for castration-resistant prostate cancer.

Galsky MD, Vogelzang NJ. Galsky MD, et al. Ann Oncol. 2010 Nov;21(11):2135-2144. doi: 10.1093/annonc/mdq050. Epub 2010 Mar 29. Ann Oncol. 2010. PMID: 20351071 Free article. Review.

10

Cabazitaxel.

Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Galsky MD, et al. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. Nat Rev Drug Discov. 2010. PMID: 20811375 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

408 results

Search Page